Abstract

A REVIEW ON A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR POTENTIATOR- IVACAFTOR

Neharika Rawat, Wasim Akhtar, M. Shaquiquzzaman, Mymoona Akhter, Asif Hussain and M. Mumtaz Alam*

ABSTRACT

Among various lethal genetic syndromes, cystic fibrosis is one of them affecting the caucasian population. Ivacaftor has emerged as the first orally manageable drug that participated & succeeded in human clinical trials for cystic fibrosis sufferers. Ivacaftor operates as a cystic fibrosis transmembrane conductance regulator (CFTR) protein potentiator and belongs to class III CFTR that involves gating mutation and is intended to maintain the opening of CFTR channel in a congruent manner. It might probably be an imperative target for pharmaceutical generic industries. In current review, our effort is on the way is to highlight the pharmacological as well as pharmaceutical profile of Ivacaftor along with correlated complexity of disease.

Keywords: Ivacaftor, cystic fibrosis, CFTR, gating mutation.